Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-25 pm EDT			After market 07:41:09 pm
724.9 ^USD	-1.00%		727.3	+0.33%

Apr. 25	Scholz pledges further support for the pharmaceutical industry	DP
Apr. 25	Scholz promises support for pharma sector in Germany as Merck invests	RE

Eli Lilly and : Q2 2020 Earnings Presentation

July 31, 2020 at 10:46 am EDT

2 0 2 0 B U S I N E S S R E S U L T S J U L Y 3 0 , 2 0 2 0

Not for promotional use

•	•

•

Not for promotional use

•

Not for promotional use

•

Not for promotional use

Not for promotional use	12

Not for promotional use

•

Not for promotional use

•

Not for promotional use

Not for promotional use	>	16

60%

43%

Semaglutide

144

130

Semaglutide

Not for promotional use

≥

KHK INHIBITOR

SARS-COV-2 MAB

NASH / Diabetes

(LY-CoV016)COVID-19

CD73 INHIBITOR

NRG4 AGONIST

Cancer

Heart Failure

GIP/GLP COAGONIST

TAU MORPHOMER

PEPTIDE Diabetes

Alzheimer's

ANGPTL3/8 MAB

SSTR4 AGONIST

CVD

Pain

GLP-1R NPA

TRPA1 ANTAGONIST

TIRZEPATIDE

Diabetes

Pain

Obesity

CV Outcomes

GGG TRI-AGONIST

D1 PAM II

ABEMACICLIB

BARICITINIB

Diabetes

Dementia

Adjuvant Breast Cancer

COVID-19

O-GLCNACASE INH

CDK7 INHIBITOR

OLARATUMAB

BARICITINIB

BARICITINIB Systemic

Alzheimer's

Cancer

Pancreatic Cancer

Alopecia Areata

Lupus Erythematosus

N3PG Aβ MAB

ERK INHIBITOR

TIRZEPATIDE

ABEMACICLIB

MIRIKIZUMAB

Alzheimer's

Cancer

NASH

Prostate Cancer

Crohn's Disease

Ulcerative Colitis

PD-1 MAB AGONIST

SERD

EPIREG/TGFα MAB

SARS-COV-2 MAB

TANEZUMAB*

EMPAGLIFLOZIN*

Immunology

Cancer

Chronic Pain

(LY-CoV555)COVID-19

Cancer Pain

Chronic Kidney Disease

PACAP38 MAB

IL-2 CONJUGATE

ANGIOPOIETIN 2 MAB

BTK INHIBITOR

EMPAGLIFLOZIN*

Pain

Immunology

COVID-19

(LOXO-305)Cancer

Heart Failure pEF

Heart Failure rEF

BTLA MAB AGONIST

GDF 15 AGONIST

CD200R MAB AGONIST

AUTOMATED INSULIN

SELPERCATINIB

Immunology

Diabetes

Immunology

DELIVERY SYS Diabetes

1L Med Thyroid Cancer

1L NSCLC

AUR A KINASE

OXYNTOMODULIN

BASAL INSULIN-FC

MEVIDALEN (D1 PAM)

TIRZEPATIDE

LEBRIKIZUMAB

INHIBITOR Cancer

Diabetes

Dementia

Diabetes

Atopic Dermatitis

IL-33 MAB

CXCR1/2L MAB

ZAGOTENEMAB (TAU

DONANEMAB (N3PG

SOLANEZUMAB

MIRIKIZUMAB

Immunology

MAB) Alzheimer's

Aβ MAB) Alzheimer's

Preclinical AD

Psoriasis

KRAS G12C

INHIBITOR

Cancer

	NME		MOVEMENT SINCE

		April 20, 2020

	NILEX		ACHIEVED MILESTONE

*	Commercial		REMOVAL
Collaboration

DULAGLUTIDE
3.0 / 4.5 mg


BARICITINIB		IXEKIZUMAB
Atopic Dermatitis		Non-Radiographic AxSpA


CONNECTED CARE		SELPERCATINIB
PREFILLED INSULIN PEN
	(RET INH) Cancer
Diabetes


TANEZUMAB*		FLORTAUCIPIR
Osteoarthritis Pain		Tau Imaging, diagnostic

✓

✓-

✓

Not for promotional use

New since last update

✓	✓	✓ ✓
			✓
✓	✓
✓			✓

✓
✓
✓	✓ ✓ ✓

✓

✓-

✓✓ ✓

✓

✓✓✓

✓

•

▪	▪

▪

Not for promotional use

•

Not for promotional use

•

Not for promotional use

•

Not for promotional use

•

Not for promotional use

≥

Not for promotional use

Attachments

Original document
Permalink

Disclaimer

Eli Lilly and Company published this content on 30 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 July 2020 14:46:08 UTC

Latest news about Eli Lilly and Company

Scholz pledges further support for the pharmaceutical industry	Apr. 25	DP
Scholz promises support for pharma sector in Germany as Merck invests	Apr. 25	RE
Global markets live: Bayer, PepsiCo, Halliburton, Spotify, Apple...	Apr. 23
Alzheimer's drug adoption in US slowed by doctors' skepticism	Apr. 23	RE
Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates	Apr. 22	RE
Eli Lilly Acquires Injectables Manufacturing Facility in Wisconsin from Nexus Pharmaceuticals	Apr. 22	MT
Eli Lilly to acquire manufacturing facility from Nexus Pharma	Apr. 22	RE
Eli Lilly: agreement to purchase a Nexus plant in the USA	Apr. 22	CF
Eli Lilly and Company entered into a definitive agreement to acquire New Injectable Medicine Manufacturing Facility of Nexus Pharmaceuticals, Inc.	Apr. 21	CI
India's Biocon developing its own version of Wegovy, clinical trial likely next year	Apr. 18	RE
Top Stories at Midday: U.S. Bancorp, Abbott, Citizens Financial, First Horizon, Prologis, ASML, Travelers Report Earnings; Tesla Asks Shareholders Vote on Musk's Compensation; Eli Lilly Sleep Apnea Drug Trials Hit Primary Endpoints	Apr. 17	MT
Jefferies Raises Eli Lilly's Price Target to $895 From $885, Buy Rating Kept	Apr. 17	MT
Trending : Eli Lilly Weight-Loss Drug Works on Sleep Apnea	Apr. 17	DJ
Swiss Stocks Jump as Earnings Bonanza Begins; Luxury Stocks Shine on LVMH Boost	Apr. 17	MT
Wall St slips as dour earnings, chip stocks weigh	Apr. 17	RE
Global markets live: LVMH, ASML, Rio Tinto, Eli Lilly, Tesla...	Apr. 17
Eli Lilly's Weight-loss Drug Improves Sleep Apnea Symptoms in Late-stage Studies	Apr. 17	MT
Sector Update: Health Care Stocks Advance Premarket Wednesday	Apr. 17	MT
Most doses of Lilly's Mounjaro and Zepbound in limited availability, US FDA says	Apr. 17	RE
The market is pinning its hopes on earnings reports	Apr. 17
Wall St set for higher open on megacaps boost; earnings, Fed comments on tap	Apr. 17	RE
Eli Lilly's Phase 3 Trials of Tirzepatide to Treat Sleep Apnea Meet Endpoints	Apr. 17	MT
Eli Lilly: positive data in sleep apnea	Apr. 17	CF
Studies Show Eli Lilly Weight-Loss Drug Helps With Sleep Apnea	Apr. 17	DJ
Eli Lilly's weight-loss drug succeeds in trials with sleep apnea patients	Apr. 17	RE

Chart Eli Lilly and Company

Duration

Period

More charts

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Sector

Pharmaceuticals

Calendar

2024-04-30 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

David Ricks, CEO of Eli Lilly: A market of over a billion people

March 12, 2024 at 02:47 pm EDT

More Strategies

Ratings for Eli Lilly and Company

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

724.9 USD

Average target price

813.3 USD

Spread / Average Target

+12.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+24.35%	653B
NOVO NORDISK A/S	+24.17%	556B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+7.95%	296B
ASTRAZENECA PLC	+13.45%	233B
NOVARTIS AG	+6.04%	201B
ROCHE HOLDING AG	-10.51%	193B
PFIZER, INC.	-12.26%	143B
AMGEN INC.	-6.47%	144B

Other Pharmaceuticals

Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Eli Lilly and : Q2 2020 Earnings Presentation

EPS Revisions